+

Visit Stations 13-16

LEADING  TAVI AND TMTI INNOVATIONS
AT NEW YORK VALVES 2026

Get NY Valves Updates

June 24–26, 2026

Join Abbott at NY Valves 2026 to learn about advancements in aortic, mitral and tricuspid valve therapies. Visit our workstations for hands-on experience on our latest Abbott technologies:

  • MitraClip™/TriClip™ G5 Transcatheter Edge-to-Edge-Repair (TEER)
  • Navitor™ Transcatheter Aortic Valve Implantation (TAVI) System
  • Tendyne™ Transcatheter Mitral Valve Replacement (TMVR)

Add to your calendar to attend featured presentations and trainings each day of the conference below.

Wednesday, June 24, 2026 

TAVI LUNCH SYMPOSIUM
12:00 PM - 1:15 PM EDT

Design Drives Strategy: How TAVI Valve Design Influences Implant Technique and Lifetime Management

Live Case Theater, Room 405, Level 4

Add to calendar

Featured Experts:

Dr. Didier Tchétché
Clinique Pasteur, Toulouse, France
Moderator

Dr. Sahil Khera
Mount Sinai
Health System

Dr. Dustin Kliner
University of Pittsburgh Medical Center

Dr. Mark Ricciardi
Glenbrook Hospital

Dr. John Saxon
UVA Health

Wednesday, June 24, 2026 

LATE-BREAKING CLINICAL SCIENCE
2:15 PM – 2:30 PM EDT

Thirty-day Outcomes After T-TEER with the TriClip System: Early Experience from the TVT Registry

Heart Team Arena, Room 406, Level 4

Add to calendar

Featured Experts:

Dr. Wayne Batchelor
Inova Schar Heart
and Vascular

Wednesday, June 24, 2026 

FDA TOWNHALL SESSION
3:25 PM – 3:30 PM EDT

The Challenges of Crossover: Lessons Learned from TRILUMINATE and Tricuspid TEER Devices

Innovation Theater, Room 410, Level 4

Add to calendar

Featured Experts:

Dr. Paul Sorajja
Banner Health

Thursday, June 25, 2026

SCIENTIFIC ABSTRACT
7:44 AM - 7:55 AM EDT 

TAVR - Long-Term Outcomes: Five-Year Outcomes of Self-expanding Intra-annular Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: The Navitor IDE Study – An Update

Moderated Abstracts Station 1, Room 503/504, Education & Training Hall, Level 5

Add to calendar

Featured Experts:

Dr. Dustin Kliner
University of Pittsburgh
Medical Center

Thursday, June 25, 2026

INNOVATION THEATER
8:41 AM - 8:53 AM EDT

Tendyne TMVR in Patients with Severe MAC:
Characterization and Stratified Outcomes by MAC Severity in the SUMMIT Trial

Innovation Theater, Room 410, Level 4

Add to calendar

Featured Experts:

Dr. Jason H. Rogers
UC Davis Health

Thursday, June 25, 2026

SCIENTIFIC ABSTRACT
9:32 AM – 9:42 AM EDT

Redefining Functional Mitral Regurgitation Severity and Outcomes: Results From the EXPANDed Studies  

Moderated Abstracts Station 2, Room 503/504, Education & Training Hall, Level 5

Add to calendar

Featured Experts:

Dr. Benjamin Peterson
Intermountain Medical Center

Thursday, June 25, 2026

SCIENTIFIC ABSTRACT
9:43 AM – 9:53 AM EDT

Impact of Ischemic Mitral Regurgitation on Clinical Outcomes: Results From the EXPANDed Studies 

Moderated Abstracts Station 2, Room 503/504, Education & Training Hall, Level 5

Add to calendar

Featured Experts:

Dr. Mahesh V. Madhavan
Columbia University Irving Medical Center

Thursday, June 25, 2026

TMTI LUNCH SYMPOSIUM
12:00 PM – 1:15 PM EDT

Interpreting Contemporary Evidence for TEER in Tricuspid and Mitral Valve Disease 

Heart Team Arena, Room 406, Level 4

Add to calendar

Featured Experts:

Dr. Jamie McCabe
Beth Israel Deaconess
Medical Center
Moderator

Dr. Anita Asgar
Northwestern
Medicine

Dr. Paul Sorajja
Banner Health

Dr. Isida Byku
Emory University

Thursday, June 25, 2026

INNOVATION THEATER
4:09 PM - 4:20 PM EDT

Innovations in Balloon-Expandable TAVR Systems: Procedural Outcomes of a Novel Balloon- Expandable TAVR (Encantor) for Aortic Stenosis: FIH and EFS Results

Innovation Theater, Room 410, Level 4

Add to calendar

Featured Experts:

Dr. Didier Tchétché
Clinique Pasteur, Toulouse, France

Thursday, June 25, 2026

VALVE COORDINATOR DINNER
6:30 PM – 8:30 PM EDT

From Evidence to Impact: How Valve Coordinators and APPs Can Optimize Treatment Decisions for Patients with Valvular Heart Disease 

Join us for an evening of collaborative discussion for valve coordinators and advanced practice providers who manage patients with valvular heart disease. We will highlight emerging data and explore what it means for clinicians who see patients in clinic, support shared decision-making, and help manage evolving treatment pathways.

Zuma, 261 Madison Ave, New York, NY 10016 

Register

Featured Experts:

Caitlin O’Callaghan Reen, CNP, FACC
Clinical Lead for Strategic and Programmatic Initiative
Massachusetts General Hospital

Dr. Nicholas J. Ruggiero
Senior Medical Director
Abbott Structural Heart

Friday, June 26, 2026 

iCOACH PROGRAM
7:00 AM – 8:15 AM EDT

T-TEER Step-by-Step (3D Nav)

iCOACH Theater, Room 502, Level 5

This content is CME/MOC accredited

Add to calendar

Friday, June 26, 2026 

LIVE CASE
10:45 AM — 11:15 AM EDT

New TMVR (CEPHEA*) 

Live Case Theater, Room 405, Level 4

*CAUTION: Investigational device. Limited by Federal (U.S.) law to investigational use only

Add to calendar

Friday, June 26, 2026 

LATE-BREAKING CLINICAL SCIENCE
11:00 AM - 11:15 AM EDT

TAVR Session II: Real-World Outcomes of TAVR with the NAVITOR Valve for Patients with Small Aortic Annuli: Results from the STS/ACC Registry

Heart Team Arena | Room 406 | Level 4

Add to calendar

Featured Experts:

Dr. Raviteja Reddy Guddeti
The Christ Hospital

Explore Abbott’s Structural Heart Portfolio

TAVI

Navitor

The Navitor transcatheter aortic valve implantation (TAVI) system is built for stable delivery, excellent hemodynamics, and long-term value. The Navitor™ Valve accommodates a wide range of anatomies, while the FlexNav™ delivery system enhances precision and access—even in challenging vessels.

Learn more about Navitor

TEER

MitraClip 

The first and only U.S.-approved TEER therapy for both primary and secondary MR, supported by 20+ years of evidence and over 300,0001 patients treated worldwide. Its proven outcomes and broad adoption make it the most widely used transcatheter mitral valve repair therapy worldwide.

Learn more about MitraClip

TriClip 

TriClip is the only TEER therapy intentionally designed for the tricuspid valve to improve quality of life and functional status in patients with symptomatic severe tricuspid regurgitation.2 Multiple randomized clinical trials show significant risk reduction in heart failure hospitalizations (HFH) across the full cohort, with consistent benefit relative to medical therapy, along with an exceptional safety profile.3-6

Learn more about TriClip

TMVR

Tendyne

Tendyne is a transcatheter mitral valve replacement system designed to treat symptomatic mitral valve dysfunction associated with severe mitral annular calcification (MAC) in patients who are deemed unsuitable for mitral valve surgery or transcatheter edge-to-edge repair; offering sustained MR reduction and improved quality of life.

Learn more about Tendyne

Don’t miss a beat—stay ahead with exclusive access to recorded symposia and the latest NY Valves 2026 insights.

MAT-2643997 v4.0 | Item approved for U.S. use only.

References
  1. Data on file at Abbott.
  2. TriClip IFU.
  3. Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: The TRILUMINATE Pivotal Randomized Trial. Circulation. March 30, 2025. doi:10.1161/CIRCULATIONAHA.125.074536
  4. Donal E, et al. Transcatheter edge-to-edge repair for severe isolated tricuspid regurgitation — extended follow-up — the Tri.Fr Randomized Clinical Trial. Presented at ACC 2026, March 29, 2026.
  5. Lurz P, Rommel KP, Schmitz T, et al. Real-world 1-year results of tricuspid edge-to-edge repair from the bRIGHT study. J Am Coll Cardiol. 2024;84(7):607-616. doi:10.1016/j.jacc.2024.05.006
  6. Tang GHL, Hahn RT, Whisenant BK, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. J Am Coll Cardiol. Published online 2025;85(3):235-246. doi:10.1016/j.jacc.2024.10.08
Important Safety Information
  • MitraClip
  • TriClip
  • Tendyne
  • Navitor

  • Rx Only

    MITRACLIP™ CLIP DELIVERY SYSTEM

    INDICATIONS FOR USE

    The MitraClip™ G5 System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.

    The MitraClip™ G5 System, when used with maximally tolerated guideline-directed medical therapy (GDMT), is indicated for the treatment of symptomatic, moderate-to-severe or severe secondary (or functional) mitral regurgitation (MR; MR ≥ Grade III per American Society of Echocardiography criteria) in patients with a left ventricular ejection fraction (LVEF) ≥ 20% and ≤ 50%, and a left ventricular end systolic dimension (LVESD) ≤ 70 mm whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.

    CONTRAINDICATIONS

    The MitraClip™ G5 System is contraindicated for use in patients with the following conditions:

    • Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation
    • Untreatable hypersensitivity to Implant components (nickel- titanium alloy, cobalt-chromium alloy)
    • Active endocarditis or other active infection of the mitral valve 

    POTENTIAL COMPLICATIONS AND ADVERSE EVENTS

    The following events have been identified as possible complications of the MitraClip™ G5 procedure:
    Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials, and drug reactions to anticoagulation, or antiplatelet drugs, additional treatment/surgery from device-related complications, atrial septal defect, bleeding, blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)), Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias), Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina), Cardiac perforation, Cardiac tamponade, chest pain, death, Dyspnea, Edema, Embolization (device or components of the device), Endocarditis, fever or hyperthermia, Fluoroscopy and Transesophageal echocardiogram (TEE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding, Hypotension / hypertension; Infection including: Septicemia; Mitral valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single leaflet device attachment (SLDA), dislodgement of previously implanted devices, tissue damage, mitral valve stenosis, worsening, persistent or residual regurgitation, nausea or vomiting, pain, Pericardial effusion, stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA), system organ failure: cardio-respiratory arrest, worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic), Thrombosis, Vascular access complications which may require additional intervention, including: wound dehiscence, bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury, Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism)

  • Rx Only

    TRICLIP™ G5 SYSTEM

    INDICATIONS

    The TriClip™ G5 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

    CONTRAINDICATIONS

    The TriClip™ G5 System is contraindicated for use in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to Implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve.

    POTENTIAL ADVERSE EVENTS

    The following events have been identified as possible complications of the TriClip™ G5 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment / surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy and Transesophageal echocardiogram (TEE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Nausea or vomiting; Pain; Pericardial effusion; Stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single leaflet device attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism).

  • Rx Only

    TENDYNE™ TRANSCATHETER MITRAL VALVE SYSTEM

    INDICATIONS FOR USE

    The Tendyne™ Transcatheter Mitral Valve System is indicated for the treatment of symptomatic severe mitral valve dysfunction (moderate-to-severe or severe mitral regurgitation (MR), severe mitral stenosis (MS), or moderate MR with moderate or greater MS) associated with severe mitral annular calcification (MAC) in patients who are deemed unsuitable for mitral valve surgery or transcatheter edge-to-edge repair by a multidisciplinary heart team.

    CONTRAINDICATIONS

    The Tendyne™ Transcatheter Mitral Valve System is contraindicated in patients with:

    • anticoagulation/antiplatelet intolerance;
    • sepsis or active endocarditis;
    • evidence of left ventricular or left atrial thrombus at risk of embolization;
    • a thin or fragile apex rendering the subject unsuitable for a transapical procedure; or
    • untreatable hypersensitivity to nickel or titanium

    Patients not deemed a candidate by the local heart team based on clinical or anatomical factors should not have the Tendyne™ Transcatheter Mitral Valve procedure.

    POTENTIAL COMPLICATIONS AND ADVERSE EVENTS

    Adverse events potentially associated with use of the Tendyne™ Transcatheter Mitral Valve System may include, but are not limited to, the following:

    Death, Adverse foreign body response, Adverse reaction to anesthesia, Allergic reaction, Anemia, Annular dissection, Aortic insufficiency, Atrial or ventricular injury, Atrial Septal Defect (resulting from transseptal mitral valvuloplasty, if performed), Bioprosthetic valve dysfunction, Bleeding complications, Blood loss which may require transfusion, Cardiac arrest, Cardiac perforation, Conduction defect with or without need for pacemaker, Cardiac arrhythmia, atrial or ventricular, Damage to cardiac tissue and/or structures, Decreased LV function and/or cardiac output, Device embolism, Device erosion, migration or malposition, Device thrombosis, Embolism (air, blood clot, calcium, tissue, etc.), Endocarditis, Esophageal irritation, stricture, or perforation, Fever, Foreign body response, Heart Failure, new or worsening, Hematoma, Hemolysis, Hypotension, Infection / Sepsis, Leaflet, chordal, papillary or ventricular rupture (resulting from mitral valvuloplasty, if performed), Liver failure, Mitral valve injury, Mitral valve prolapse / stenosis, Myocardial infarction, Obstruction, Pain, Pleural effusion, Pulmonary embolism, Pulmonary hypertension, Paravalvular leak, Pericardial effusion / tamponade, Renal insufficiency or failure, Respiratory difficulty, insufficiency or failure, Stroke or transient ischemic attack, Tear or damage to device, Vascular and access-related complications, Worsening of mitral regurgitation.

  • Rx Only

    NAVITOR™ TRANSCATHETER AORTIC VALVE IMPLANTATION SYSTEM

    INDICATIONS

    The Navitor™ Transcatheter Aortic Valve Implantation System is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator).

    CONTRAINDICATIONS  

    The valve is contraindicated for patients with inability to tolerate antiplatelet/anticoagulant therapy or nitinol alloy (nickel and titanium), or who have active infections, including endocarditis.

    POTENTIAL ADVERSE EVENTS  

    Adverse events potentially associated with the use of transcatheter bioprosthetic heart valves include but are not limited to: access site complications (e.g., pain, bleeding, infection, hematoma, pseudoaneurysm, etc.); acute coronary obstruction; acute myocardial infarction; allergic reaction to antiplatelet agents, contrast medium, or valve components; aortic rupture; ascending aorta trauma; atrio-ventricular node block; cardiac arrhythmias; conduction system injury; conversion to open surgical procedure; death; dissection; embolism; emergent balloon valvuloplasty; emergent percutaneous coronary intervention (PCI); emergent surgery (i.e., coronary artery bypass, heart valve replacement); endocarditis; explantation; heart failure; hemodynamic compromise; hemolysis; hemolytic anemia; hemorrhage; hypotension or hypertension; infection; myocardial ischemia; mitral valve insufficiency; multi-organ failure; non-structural dysfunction (i.e., entrapment by pannus, paravalvular leak, inappropriate sizing or positioning); pannus; pericardial effusion; perforation of the myocardium, ventricle, or a blood vessel; permanent disability; permanent pacemaker; regurgitation; renal insufficiency or renal failure; reoperation; respiratory failure; sepsis; stroke; structural deterioration (i.e., calcification, leaflet tear); thrombosis; tamponade; transfusion; valve embolization or migration; vessel dissection or spasm.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. VISITOR INTERNATIONAL VISITOR

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+